Genmab (GMAB) reported Thursday a Q1 net profit of $0.83 per diluted share, down from $3.05 a year earlier.

Analysts polled by FactSet expected $0.16.

Revenue for the three months ended March 31 was $896 million, up from $715 million a year earlier.

Analysts surveyed by FactSet expected $905.8 million.

The firm kept its 2026 financial guidance, including for revenue of $4.07 billion to $4.40 billion. Analysts expect $4.33 billion.

Shares were down over 3% in afternoon trading.

Price: 27.04, Change: -0.85, Percent Change: -3.05